Study to Evaluate Tezepelumab on Airway Inflammation in Adults with Uncontrolled Asthma (CASCADE)

Trial Identifier: D5180C00013
Sponsor:AstraZeneca
Collaborator:
Amgen
NCTID:NCT03688074
Start Date:November 2018
Primary Completion Date: November 2020
Study Completion Date: November 2020
Condition: Asthma; Immune, Inflammatory & Infections - Other

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

LanguageDescription
Danish Translation
English version
French Translation
German Translation
Spanish Translation

Trial Locations

CountryLocation
Canada, AB Calgary, AB, Canada, T2N 4Z6
Canada, BC Vancouver, BC, Canada, V5Z 1M9
United States of America, TX Galveston, TX, United States of America, 77555
United States of America, MA Boston, MA, United States of America, 02115
United States of America, PA Pittsburgh, PA, United States of America, 15213
Germany Frankfurt, Germany, 60596
Germany Frankfurt/Main, Germany, 60389
Germany Grosshansdorf, Germany, 22927
Germany Landsberg, Germany, 86899
United Kingdom Cambridge, United Kingdom, CB2 0QQ
United Kingdom Headington, United Kingdom, OX3 9DU
United Kingdom Leicester, United Kingdom, LE3 9QP
United Kingdom Liverpool, United Kingdom, L7 8XP
United Kingdom London, United Kingdom, W1G 8HU
United Kingdom Nottingham, United Kingdom, NG5 1PB
United Kingdom Wythenshawe, United Kingdom, M23 9QZ
United States of America, CO Denver, CO, United States of America, 80206
United States of America, CT New Haven, CT, United States of America, 06510
Canada, QC Montreal, QC, Canada, H4A 3J1
Canada, QC Quebec, QC, Canada, G1V 4G5
Denmark Aarhus N, Denmark, 8200
Denmark Ålborg, Denmark, 9000
Denmark Hvidovre, Denmark, 2650
Denmark København NV, Denmark, 2400
Denmark Naestved, Denmark, 4700
Denmark Odense C, Denmark, 5000
Denmark Vejle, Denmark, 7100
Canada, ON Hamilton, ON, Canada, L8N 3Z5
Canada, ON Ottawa, ON, Canada, K1H 8L6